Orange Book product · Brand (NDA)
NORVIR
RITONAVIR
At a glance
Feb 10, 2010
Approved
Brand (NDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Feb 10, 2010
16 yr 7 mo ago
Today
Pharmaceutical detail
Active ingredient
RITONAVIR
Strength
100MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
NDA 022417
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
No
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2017NORVIRBrand (NDA)
NDA 209512 · ABBVIE
- 1999NORVIRBrand (NDA)
NDA 020945 · ABBVIE
- 1996NORVIRBrand (NDA)
NDA 020680 · ABBOTT
- 1996NORVIRBrand (NDA)
NDA 020659 · ABBVIE
- 2024RITONAVIRGeneric (ANDA)
ANDA 205024 · QUAGEN
- 2022RITONAVIRGeneric (ANDA)
ANDA 203759 · CIPLA
- 2020RITONAVIRGeneric (ANDA)
ANDA 205801 · HIKMA
- 2018RITONAVIRGeneric (ANDA)
ANDA 208890 · AMNEAL
- 2018RITONAVIRGeneric (ANDA)
ANDA 206614 · AUROBINDO PHARMA LTD
- 2018RITONAVIRGeneric (ANDA)
ANDA 204587 · HETERO LABS LTD III
- 2015RITONAVIRGeneric (ANDA)
ANDA 202573 · CIPLA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
